Albuminar-20 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established role of albumin in volume expansion, growth of critical care admissions, rising surgical procedures, clinical acceptance of plasma products, hospital protocol standardization.

The growth in the forecast period can be attributed to growth in icu admissions, expansion of trauma care centers, increasing aging population, demand for stable plasma derivatives, improved plasma fractionation capacity. Major trends in the forecast period include sustained demand for high concentration albumin solutions, growing use in critical care and shock management, increased application in burn and trauma care, preference for plasma derived volume expanders, expansion of intensive care infrastructure.

The growing prevalence of chronic diseases is expected to drive the growth of the albuminar-20 market in the coming years. Chronic diseases are long-term health conditions that typically progress gradually, such as diabetes, cardiovascular disease, and arthritis, and often require continuous medical care and lifestyle adjustments to manage symptoms and prevent complications. The rise in chronic diseases is largely attributed to unhealthy lifestyle habits, including poor nutrition, lack of physical activity, and smoking, which increase the risk of conditions such as diabetes, heart disease, and obesity. Albuminar-20 supports the management of chronic diseases by replenishing plasma volume and improving fluid balance in patients with conditions such as liver cirrhosis, renal disorders, and heart failure. It helps minimize complications associated with hypoalbuminemia, contributing to more stable treatment outcomes and improved overall patient health. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the albuminar-20 market.

The rise in surgical procedures is expected to fuel the growth of the albuminar-20 market going forward. Surgical procedures involve medical operations performed to diagnose, treat, or manage diseases, injuries, or other health conditions using manual or instrumental methods. The growth in surgical volumes is primarily driven by an aging population, which has led to a higher demand for procedures such as joint replacements and cardiovascular surgeries. Albuminar-20 supports surgical care by facilitating effective fluid resuscitation, making it vital for managing blood loss and maintaining hemodynamic stability during operations. It helps reduce perioperative complications by rapidly restoring plasma volume, thereby improving surgical outcomes and enhancing patient recovery. For instance, in May 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, 778,500 patients were admitted for surgery from public hospital elective surgery waiting lists in 2023-24, reflecting a 5.8% increase compared with 2022-23. Therefore, the increase in surgical procedures is driving the growth of the albuminar-20 market.

Rising healthcare expenditure is expected to support the growth of the albuminar-20 market in the coming years. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatments, hospital care, pharmaceuticals, and public health programs, by governments, organizations, and individuals. The growth in healthcare spending is largely driven by the increasing prevalence of chronic diseases, which often require prolonged and expensive treatments. Higher healthcare expenditure supports the adoption of albuminar-20 by improving access to advanced therapies and ensuring the availability of essential plasma-derived treatments in hospitals and specialized care settings. It also enables healthcare systems to invest in enhanced patient management for conditions requiring albumin therapy, leading to improved clinical outcomes and greater treatment efficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% higher growth rate compared to 2022. Therefore, rising healthcare expenditure is driving the growth of the albuminar-20 market.

Major companies operating in the albuminar-20 market are Grifols SA.

North America was the largest region in the albuminar-20 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albuminar-20 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albuminar-20 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the albuminar-20 market by increasing costs for imported plasma raw materials, fractionation equipment, and sterile packaging components. These effects are more pronounced in regions dependent on plasma imports such as asia pacific and emerging economies. Hospital procurement costs have risen, affecting critical care budgets. However, tariffs have encouraged local plasma collection and processing investments. This strengthens domestic supply chains and improves long term product availability.

The albuminar-20 market research report is one of a series of new reports that provides albuminar-20 market statistics, including albuminar-20 industry global market size, regional shares, competitors with a albuminar-20 market share, detailed albuminar-20 market segments, market trends and opportunities, and any further data you may need to thrive in the albuminar-20 industry. This albuminar-20 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albuminar-20 is a sterile 20% solution of human serum albumin used as a plasma volume expander and for various therapeutic applications. It functions by maintaining oncotic pressure, helping to restore and stabilize blood volume in conditions such as hypovolemia, burns, and hypoalbuminemia. Derived from pooled human plasma and processed to minimize the risk of infectious agents, Albuminar-20 is primarily utilized in critical care settings.

The main formulations in the Albuminar-20 market include human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin (HSA) is a protein present in human blood plasma that plays a vital role in maintaining oncotic pressure and transporting substances such as hormones, fatty acids, and medications. Its indications include shock management, burn treatment, and hypoalbuminemia. Distribution channels include hospitals and clinics, as well as retail and specialty pharmacies, with end users comprising hospitals and clinics, the pharmaceutical and biotechnology industry, and research institutions.

The albuminar-20 market consists of sales of human serum albumin solutions and protein replacement or plasma volume expansion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.